Search filters

List of works by Michael Gulrajani

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity ⬇️

scholarly article

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

scientific article published on 7 September 2017

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

scientific article published on 01 April 2020

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

scientific article published on 08 January 2020

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

scientific article published on 20 March 2020

Discovery of quinoline-based irreversible BTK inhibitors

scientific article published on 13 May 2020

Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib

scientific article published on 13 February 2020

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

scientific article

Single Cell Network Profiling as a Platform to Reveal Leukemia-Specific Signaling Signatures and Sensitivity to Kinase Inhibitor Therapies ⬇️

scholarly article

Single cell network profiling assay in bladder cancer ⬇️

scientific article published on January 8, 2013

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

scientific article published on 30 November 2016

Paulina is supported by:

About Paulina

Help